APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antifibrotic Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Antifibrotic Drug Industry Growth and Trends Forecast to 2032

20 December 2025112 pages

Choose your research edition.

Industry ResearchAntifibrotic Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Antifibrotic Drug Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Antifibrotic Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antifibrotic Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Antifibrotic Drug Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Antifibrotic Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Antifibrotic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Antifibrotic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antifibrotic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antifibrotic Drug include Accord Healthcare, Amneal Pharmaceuticals, Apotex, Beacon Pharma, Boehringer Ingelheim, Eskayef Pharmaceuticals, ScieGen Pharmaceuticals, Gyre Pharmaceuticals and Kawin, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Antifibrotic Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Antifibrotic Drug market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Antifibrotic Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Antifibrotic Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Antifibrotic Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Antifibrotic Drug Market by Company

Accord Healthcare

Amneal Pharmaceuticals

Apotex

Beacon Pharma

Boehringer Ingelheim

Eskayef Pharmaceuticals

ScieGen Pharmaceuticals

Gyre Pharmaceuticals

Kawin

Roche

Qilu Pharmaceutical

PuraCap

Sandoz

CSPC Pharmaceutical Group

Kelun Pharmaceutical

Teva

Antifibrotic Drug Segment by Type

Nintedanib

Pirfenidone

Antifibrotic Drug Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Antifibrotic Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antifibrotic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antifibrotic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antifibrotic Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antifibrotic Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Antifibrotic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Nintedanib Table 2. Major Company of Pirfenidone Table 3. Global Antifibrotic Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Antifibrotic Drug Sales by Type (2021-2026) & (k units) Table 5. Global Antifibrotic Drug Sales Market Share in Volume by Type (2021-2026) Table 6. Global Antifibrotic Drug Sales by Type (2021-2026) & (US$ Million) Table 7. Global Antifibrotic Drug Sales Market Share in Value by Type (2021-2026) Table 8. Global Antifibrotic Drug Price by Type (2021-2026) & (US$/unit) Table 9. Global Antifibrotic Drug Sales by Type (2027-2032) & (k units) Table 10. Global Antifibrotic Drug Sales Market Share in Volume by Type (2027-2032) Table 11. Global Antifibrotic Drug Sales by Type (2027-2032) & (US$ Million) Table 12. Global Antifibrotic Drug Sales Market Share in Value by Type (2027-2032) Table 13. Global Antifibrotic Drug Price by Type (2027-2032) & (US$/unit) Table 14. North America Antifibrotic Drug Sales by Type (2021-2026) & (k units) Table 15. North America Antifibrotic Drug Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Antifibrotic Drug Sales by Type (2021-2026) & (k units) Table 17. Europe Antifibrotic Drug Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Antifibrotic Drug Sales by Type (2021-2026) & (k units) Table 19. Asia-Pacific Antifibrotic Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Antifibrotic Drug Sales by Type (2021-2026) & (k units) Table 21. Latin America Antifibrotic Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Antifibrotic Drug Sales by Type (2021-2026) & (k units) Table 23. Middle East and Africa Antifibrotic Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Antifibrotic Drug Industry Trends Table 25. Antifibrotic Drug Industry Drivers Table 26. Antifibrotic Drug Industry Opportunities and Challenges Table 27. Antifibrotic Drug Industry Restraints Table 28. Global Antifibrotic Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Antifibrotic Drug Revenue Market Share by Company (2021-2026) Table 30. Global Antifibrotic Drug Sales by Company (2021-2026) & (k units) Table 31. Global Antifibrotic Drug Sales Share by Company (2021-2026) Table 32. Global Antifibrotic Drug Market Price by Company (2021-2026) & (US$/unit) Table 33. Global Antifibrotic Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Antifibrotic Drug Major Company Production Sites and Headquarters Table 35. Global Antifibrotic Drug Company, Product Type & Application Table 36. Global Antifibrotic Drug Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Antifibrotic Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Antifibrotic Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Antifibrotic Drug Sales by Region (2021-2026) & (k units) Table 41. Global Antifibrotic Drug Sales Market Share in Volume by Region (2021-2026) Table 42. Global Antifibrotic Drug Sales by Region (2021-2026) & (US$ Million) Table 43. Global Antifibrotic Drug Sales Market Share in Value by Region (2021-2026) Table 44. Global Antifibrotic Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 45. Global Antifibrotic Drug Sales by Region (2027-2032) & (k units) Table 46. Global Antifibrotic Drug Sales Market Share in Volume by Region (2027-2032) Table 47. Global Antifibrotic Drug Sales by Region (2027-2032) & (US$ Million) Table 48. Global Antifibrotic Drug Sales Market Share in Value by Region (2027-2032) Table 49. Global Antifibrotic Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 50. Global Antifibrotic Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Antifibrotic Drug Sales by Application (2021-2026) & (k units) Table 52. Global Antifibrotic Drug Sales Market Share in Volume by Application (2021-2026) Table 53. Global Antifibrotic Drug Sales by Application (2021-2026) & (US$ Million) Table 54. Global Antifibrotic Drug Sales Market Share in Value by Application (2021-2026) Table 55. Global Antifibrotic Drug Price by Application (2021-2026) & (US$/unit) Table 56. Global Antifibrotic Drug Sales by Application (2027-2032) & (k units) Table 57. Global Antifibrotic Drug Sales Market Share in Volume by Application (2027-2032) Table 58. Global Antifibrotic Drug Sales by Application (2027-2032) & (US$ Million) Table 59. Global Antifibrotic Drug Sales Market Share in Value by Application (2027-2032) Table 60. Global Antifibrotic Drug Price by Application (2027-2032) & (US$/unit) Table 61. North America Antifibrotic Drug Sales by Application (2021-2026) & (k units) Table 62. North America Antifibrotic Drug Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Antifibrotic Drug Sales by Application (2021-2026) & (k units) Table 64. Europe Antifibrotic Drug Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Antifibrotic Drug Sales by Application (2021-2026) & (k units) Table 66. Asia-Pacific Antifibrotic Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Antifibrotic Drug Sales by Application (2021-2026) & (k units) Table 68. Latin America Antifibrotic Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Antifibrotic Drug Sales by Application (2021-2026) & (k units) Table 70. Middle East and Africa Antifibrotic Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Accord Healthcare Company Information Table 72. Accord Healthcare Business Overview Table 73. Accord Healthcare Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Accord Healthcare Antifibrotic Drug Product Portfolio Table 75. Accord Healthcare Recent Development Table 76. Amneal Pharmaceuticals Company Information Table 77. Amneal Pharmaceuticals Business Overview Table 78. Amneal Pharmaceuticals Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Amneal Pharmaceuticals Antifibrotic Drug Product Portfolio Table 80. Amneal Pharmaceuticals Recent Development Table 81. Apotex Company Information Table 82. Apotex Business Overview Table 83. Apotex Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Apotex Antifibrotic Drug Product Portfolio Table 85. Apotex Recent Development Table 86. Beacon Pharma Company Information Table 87. Beacon Pharma Business Overview Table 88. Beacon Pharma Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Beacon Pharma Antifibrotic Drug Product Portfolio Table 90. Beacon Pharma Recent Development Table 91. Boehringer Ingelheim Company Information Table 92. Boehringer Ingelheim Business Overview Table 93. Boehringer Ingelheim Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Boehringer Ingelheim Antifibrotic Drug Product Portfolio Table 95. Boehringer Ingelheim Recent Development Table 96. Eskayef Pharmaceuticals Company Information Table 97. Eskayef Pharmaceuticals Business Overview Table 98. Eskayef Pharmaceuticals Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Eskayef Pharmaceuticals Antifibrotic Drug Product Portfolio Table 100. Eskayef Pharmaceuticals Recent Development Table 101. ScieGen Pharmaceuticals Company Information Table 102. ScieGen Pharmaceuticals Business Overview Table 103. ScieGen Pharmaceuticals Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. ScieGen Pharmaceuticals Antifibrotic Drug Product Portfolio Table 105. ScieGen Pharmaceuticals Recent Development Table 106. Gyre Pharmaceuticals Company Information Table 107. Gyre Pharmaceuticals Business Overview Table 108. Gyre Pharmaceuticals Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Gyre Pharmaceuticals Antifibrotic Drug Product Portfolio Table 110. Gyre Pharmaceuticals Recent Development Table 111. Kawin Company Information Table 112. Kawin Business Overview Table 113. Kawin Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Kawin Antifibrotic Drug Product Portfolio Table 115. Kawin Recent Development Table 116. Roche Company Information Table 117. Roche Business Overview Table 118. Roche Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Roche Antifibrotic Drug Product Portfolio Table 120. Roche Recent Development Table 121. Qilu Pharmaceutical Company Information Table 122. Qilu Pharmaceutical Business Overview Table 123. Qilu Pharmaceutical Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. Qilu Pharmaceutical Antifibrotic Drug Product Portfolio Table 125. Qilu Pharmaceutical Recent Development Table 126. PuraCap Company Information Table 127. PuraCap Business Overview Table 128. PuraCap Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. PuraCap Antifibrotic Drug Product Portfolio Table 130. PuraCap Recent Development Table 131. Sandoz Company Information Table 132. Sandoz Business Overview Table 133. Sandoz Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. Sandoz Antifibrotic Drug Product Portfolio Table 135. Sandoz Recent Development Table 136. CSPC Pharmaceutical Group Company Information Table 137. CSPC Pharmaceutical Group Business Overview Table 138. CSPC Pharmaceutical Group Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 139. CSPC Pharmaceutical Group Antifibrotic Drug Product Portfolio Table 140. CSPC Pharmaceutical Group Recent Development Table 141. Kelun Pharmaceutical Company Information Table 142. Kelun Pharmaceutical Business Overview Table 143. Kelun Pharmaceutical Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 144. Kelun Pharmaceutical Antifibrotic Drug Product Portfolio Table 145. Kelun Pharmaceutical Recent Development Table 146. Teva Company Information Table 147. Teva Business Overview Table 148. Teva Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 149. Teva Antifibrotic Drug Product Portfolio Table 150. Teva Recent Development Table 151. North America Antifibrotic Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 152. North America Antifibrotic Drug Sales by Country (2021-2026) & (k units) Table 153. North America Antifibrotic Drug Sales Market Share by Country (2021-2026) Table 154. North America Antifibrotic Drug Sales Forecast by Country (2027-2032) & (k units) Table 155. North America Antifibrotic Drug Sales Market Share Forecast by Country (2027-2032) Table 156. North America Antifibrotic Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. North America Antifibrotic Drug Market Size by Country (2021-2026) & (US$ Million) Table 158. North America Antifibrotic Drug Market Share by Country (2021-2026) Table 159. North America Antifibrotic Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. North America Antifibrotic Drug Market Share Forecast by Country (2027-2032) Table 161. Europe Antifibrotic Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 162. Europe Antifibrotic Drug Sales by Country (2021-2026) & (k units) Table 163. Europe Antifibrotic Drug Sales Market Share by Country (2021-2026) Table 164. Europe Antifibrotic Drug Sales Forecast by Country (2027-2032) & (k units) Table 165. Europe Antifibrotic Drug Sales Market Share Forecast by Country (2027-2032) Table 166. Europe Antifibrotic Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Europe Antifibrotic Drug Market Size by Country (2021-2026) & (US$ Million) Table 168. Europe Antifibrotic Drug Market Share by Country (2021-2026) Table 169. Europe Antifibrotic Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Europe Antifibrotic Drug Market Share Forecast by Country (2027-2032) Table 171. Asia-Pacific Antifibrotic Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 172. Asia-Pacific Antifibrotic Drug Sales by Country (2021-2026) & (k units) Table 173. Asia-Pacific Antifibrotic Drug Sales Market Share by Country (2021-2026) Table 174. Asia-Pacific Antifibrotic Drug Sales Forecast by Country (2027-2032) & (k units) Table 175. Asia-Pacific Antifibrotic Drug Sales Market Share Forecast by Country (2027-2032) Table 176. Asia-Pacific Antifibrotic Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Asia-Pacific Antifibrotic Drug Market Size by Country (2021-2026) & (US$ Million) Table 178. Asia-Pacific Antifibrotic Drug Market Share by Country (2021-2026) Table 179. Asia-Pacific Antifibrotic Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Asia-Pacific Antifibrotic Drug Market Share Forecast by Country (2027-2032) Table 181. Latin America Antifibrotic Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 182. Latin America Antifibrotic Drug Sales by Country (2021-2026) & (k units) Table 183. Latin America Antifibrotic Drug Sales Market Share by Country (2021-2026) Table 184. Latin America Antifibrotic Drug Sales Forecast by Country (2027-2032) & (k units) Table 185. Latin America Antifibrotic Drug Sales Market Share Forecast by Country (2027-2032) Table 186. Latin America Antifibrotic Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 187. Latin America Antifibrotic Drug Market Size by Country (2021-2026) & (US$ Million) Table 188. Latin America Antifibrotic Drug Market Share by Country (2021-2026) Table 189. Latin America Antifibrotic Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 190. Latin America Antifibrotic Drug Market Share Forecast by Country (2027-2032) Table 191. Middle East and Africa Antifibrotic Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 192. Middle East and Africa Antifibrotic Drug Sales by Country (2021-2026) & (k units) Table 193. Middle East and Africa Antifibrotic Drug Sales Market Share by Country (2021-2026) Table 194. Middle East and Africa Antifibrotic Drug Sales Forecast by Country (2027-2032) & (k units) Table 195. Middle East and Africa Antifibrotic Drug Sales Market Share Forecast by Country (2027-2032) Table 196. Middle East and Africa Antifibrotic Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 197. Middle East and Africa Antifibrotic Drug Market Size by Country (2021-2026) & (US$ Million) Table 198. Middle East and Africa Antifibrotic Drug Market Share by Country (2021-2026) Table 199. Middle East and Africa Antifibrotic Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 200. Middle East and Africa Antifibrotic Drug Market Share Forecast by Country (2027-2032) Table 201. Key Raw Materials Table 202. Raw Materials Key Suppliers Table 203. Antifibrotic Drug Distributors List Table 204. Antifibrotic Drug Customers List Table 205. Research Programs/Design for This Report Table 206. Authors List of This Report Table 207. Secondary Sources Table 208. Primary Sources List of Figures Figure 1. Antifibrotic Drug Image Figure 2. Global Antifibrotic Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antifibrotic Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Antifibrotic Drug Sales (2021-2032) & (k units) Figure 5. Nintedanib Image Figure 6. Global Nintedanib Sales YoY Growth (2021-2032) & (k units) Figure 7. Pirfenidone Image Figure 8. Global Pirfenidone Sales YoY Growth (2021-2032) & (k units) Figure 9. Global Antifibrotic Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Antifibrotic Drug Market Share by Type 2025 VS 2032 Figure 11. North America Antifibrotic Drug Sales Market Share in Volume by Type in 2025 Figure 12. North America Antifibrotic Drug Sales Market Share in Value by Type in 2025 Figure 13. Europe Antifibrotic Drug Sales Market Share in Volume by Type in 2025 Figure 14. Europe Antifibrotic Drug Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Antifibrotic Drug Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Antifibrotic Drug Sales Market Share in Value by Type in 2025 Figure 17. Latin America Antifibrotic Drug Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Antifibrotic Drug Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Antifibrotic Drug Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Antifibrotic Drug Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Antifibrotic Drug Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital and Clinic Image Figure 24. Global Hospital and Clinic Sales YoY Growth (2021-2032) & (k units) Figure 25. Retail Pharmacies Image Figure 26. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (k units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 29. Global Antifibrotic Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Antifibrotic Drug Market Share by Application 2025 VS 2032 Figure 31. North America Antifibrotic Drug Sales Market Share in Volume by Application in 2025 Figure 32. North America Antifibrotic Drug Sales Market Share in Value by Application in 2025 Figure 33. Europe Antifibrotic Drug Sales Market Share in Volume by Application in 2025 Figure 34. Europe Antifibrotic Drug Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Antifibrotic Drug Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Antifibrotic Drug Sales Market Share in Value by Application in 2025 Figure 37. Latin America Antifibrotic Drug Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Antifibrotic Drug Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Antifibrotic Drug Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Antifibrotic Drug Sales Market Share in Value by Application in 2025 Figure 41. North America Antifibrotic Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 42. North America Antifibrotic Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Antifibrotic Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Antifibrotic Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Antifibrotic Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. Europe Antifibrotic Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Antifibrotic Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Antifibrotic Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Antifibrotic Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Asia-Pacific Antifibrotic Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Antifibrotic Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Antifibrotic Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Antifibrotic Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Latin America Antifibrotic Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Antifibrotic Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Antifibrotic Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Antifibrotic Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Middle East and Africa Antifibrotic Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Antifibrotic Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Antifibrotic Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Antifibrotic Drug Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Antifibrotic Drug Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Nintedanib
  • Pirfenidone
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Accord Healthcare
  • Amneal Pharmaceuticals
  • Apotex
  • Beacon Pharma
  • Boehringer Ingelheim
  • Eskayef Pharmaceuticals
  • ScieGen Pharmaceuticals
  • Gyre Pharmaceuticals
  • Kawin
  • Roche
  • Qilu Pharmaceutical
  • PuraCap
  • Sandoz
  • CSPC Pharmaceutical Group
  • Kelun Pharmaceutical
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antifibrotic Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Antifibrotic Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Antifibrotic Drug Market by Type
  6. 1.3.1 Nintedanib
  7. 1.3.2 Pirfenidone
  8. 1.4 Global Antifibrotic Drug Market Size by Type
  9. 1.4.1 Global Antifibrotic Drug Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Antifibrotic Drug Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Antifibrotic Drug Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Antifibrotic Drug Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Antifibrotic Drug Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Antifibrotic Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Antifibrotic Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Antifibrotic Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Antifibrotic Drug Industry Trends
  2. 2.2 Antifibrotic Drug Industry Drivers
  3. 2.3 Antifibrotic Drug Industry Opportunities and Challenges
  4. 2.4 Antifibrotic Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Antifibrotic Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Antifibrotic Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Antifibrotic Drug Price (2021-2026)
  4. 3.4 Global Antifibrotic Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antifibrotic Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Antifibrotic Drug Company, Product Type & Application
  7. 3.7 Global Antifibrotic Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antifibrotic Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antifibrotic Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antifibrotic Drug Tier 1, Tier 2, and Tier 3
4 Antifibrotic Drug Regional Status and Outlook
  1. 4.1 Global Antifibrotic Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Antifibrotic Drug Historic Market Size by Region
  3. 4.2.1 Global Antifibrotic Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Antifibrotic Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Antifibrotic Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Antifibrotic Drug Forecasted Market Size by Region
  7. 4.3.1 Global Antifibrotic Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Antifibrotic Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Antifibrotic Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Antifibrotic Drug by Application
  1. 5.1 Antifibrotic Drug Market by Application
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Antifibrotic Drug Market Size by Application
  6. 5.2.1 Global Antifibrotic Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Antifibrotic Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Antifibrotic Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Antifibrotic Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Antifibrotic Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Antifibrotic Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Antifibrotic Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Antifibrotic Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Accord Healthcare
  2. 6.1.1 Accord Healthcare Company Information
  3. 6.1.2 Accord Healthcare Business Overview
  4. 6.1.3 Accord Healthcare Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Accord Healthcare Antifibrotic Drug Product Portfolio
  6. 6.1.5 Accord Healthcare Recent Developments
  7. 6.2 Amneal Pharmaceuticals
  8. 6.2.1 Amneal Pharmaceuticals Company Information
  9. 6.2.2 Amneal Pharmaceuticals Business Overview
  10. 6.2.3 Amneal Pharmaceuticals Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Amneal Pharmaceuticals Antifibrotic Drug Product Portfolio
  12. 6.2.5 Amneal Pharmaceuticals Recent Developments
  13. 6.3 Apotex
  14. 6.3.1 Apotex Company Information
  15. 6.3.2 Apotex Business Overview
  16. 6.3.3 Apotex Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Apotex Antifibrotic Drug Product Portfolio
  18. 6.3.5 Apotex Recent Developments
  19. 6.4 Beacon Pharma
  20. 6.4.1 Beacon Pharma Company Information
  21. 6.4.2 Beacon Pharma Business Overview
  22. 6.4.3 Beacon Pharma Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Beacon Pharma Antifibrotic Drug Product Portfolio
  24. 6.4.5 Beacon Pharma Recent Developments
  25. 6.5 Boehringer Ingelheim
  26. 6.5.1 Boehringer Ingelheim Company Information
  27. 6.5.2 Boehringer Ingelheim Business Overview
  28. 6.5.3 Boehringer Ingelheim Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Boehringer Ingelheim Antifibrotic Drug Product Portfolio
  30. 6.5.5 Boehringer Ingelheim Recent Developments
  31. 6.6 Eskayef Pharmaceuticals
  32. 6.6.1 Eskayef Pharmaceuticals Company Information
  33. 6.6.2 Eskayef Pharmaceuticals Business Overview
  34. 6.6.3 Eskayef Pharmaceuticals Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Eskayef Pharmaceuticals Antifibrotic Drug Product Portfolio
  36. 6.6.5 Eskayef Pharmaceuticals Recent Developments
  37. 6.7 ScieGen Pharmaceuticals
  38. 6.7.1 ScieGen Pharmaceuticals Company Information
  39. 6.7.2 ScieGen Pharmaceuticals Business Overview
  40. 6.7.3 ScieGen Pharmaceuticals Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 ScieGen Pharmaceuticals Antifibrotic Drug Product Portfolio
  42. 6.7.5 ScieGen Pharmaceuticals Recent Developments
  43. 6.8 Gyre Pharmaceuticals
  44. 6.8.1 Gyre Pharmaceuticals Company Information
  45. 6.8.2 Gyre Pharmaceuticals Business Overview
  46. 6.8.3 Gyre Pharmaceuticals Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Gyre Pharmaceuticals Antifibrotic Drug Product Portfolio
  48. 6.8.5 Gyre Pharmaceuticals Recent Developments
  49. 6.9 Kawin
  50. 6.9.1 Kawin Company Information
  51. 6.9.2 Kawin Business Overview
  52. 6.9.3 Kawin Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Kawin Antifibrotic Drug Product Portfolio
  54. 6.9.5 Kawin Recent Developments
  55. 6.10 Roche
  56. 6.10.1 Roche Company Information
  57. 6.10.2 Roche Business Overview
  58. 6.10.3 Roche Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Roche Antifibrotic Drug Product Portfolio
  60. 6.10.5 Roche Recent Developments
  61. 6.11 Qilu Pharmaceutical
  62. 6.11.1 Qilu Pharmaceutical Company Information
  63. 6.11.2 Qilu Pharmaceutical Business Overview
  64. 6.11.3 Qilu Pharmaceutical Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Qilu Pharmaceutical Antifibrotic Drug Product Portfolio
  66. 6.11.5 Qilu Pharmaceutical Recent Developments
  67. 6.12 PuraCap
  68. 6.12.1 PuraCap Company Information
  69. 6.12.2 PuraCap Business Overview
  70. 6.12.3 PuraCap Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 PuraCap Antifibrotic Drug Product Portfolio
  72. 6.12.5 PuraCap Recent Developments
  73. 6.13 Sandoz
  74. 6.13.1 Sandoz Company Information
  75. 6.13.2 Sandoz Business Overview
  76. 6.13.3 Sandoz Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Sandoz Antifibrotic Drug Product Portfolio
  78. 6.13.5 Sandoz Recent Developments
  79. 6.14 CSPC Pharmaceutical Group
  80. 6.14.1 CSPC Pharmaceutical Group Company Information
  81. 6.14.2 CSPC Pharmaceutical Group Business Overview
  82. 6.14.3 CSPC Pharmaceutical Group Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 CSPC Pharmaceutical Group Antifibrotic Drug Product Portfolio
  84. 6.14.5 CSPC Pharmaceutical Group Recent Developments
  85. 6.15 Kelun Pharmaceutical
  86. 6.15.1 Kelun Pharmaceutical Company Information
  87. 6.15.2 Kelun Pharmaceutical Business Overview
  88. 6.15.3 Kelun Pharmaceutical Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Kelun Pharmaceutical Antifibrotic Drug Product Portfolio
  90. 6.15.5 Kelun Pharmaceutical Recent Developments
  91. 6.16 Teva
  92. 6.16.1 Teva Company Information
  93. 6.16.2 Teva Business Overview
  94. 6.16.3 Teva Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Teva Antifibrotic Drug Product Portfolio
  96. 6.16.5 Teva Recent Developments
7 North America by Country
  1. 7.1 North America Antifibrotic Drug Sales by Country
  2. 7.1.1 North America Antifibrotic Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Antifibrotic Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Antifibrotic Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Antifibrotic Drug Market Size by Country
  6. 7.2.1 North America Antifibrotic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Antifibrotic Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Antifibrotic Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Antifibrotic Drug Sales by Country
  2. 8.1.1 Europe Antifibrotic Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Antifibrotic Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Antifibrotic Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Antifibrotic Drug Market Size by Country
  6. 8.2.1 Europe Antifibrotic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Antifibrotic Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Antifibrotic Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Antifibrotic Drug Sales by Country
  2. 9.1.1 Asia-Pacific Antifibrotic Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Antifibrotic Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Antifibrotic Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Antifibrotic Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Antifibrotic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Antifibrotic Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Antifibrotic Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Antifibrotic Drug Sales by Country
  2. 10.1.1 South America Antifibrotic Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Antifibrotic Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Antifibrotic Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Antifibrotic Drug Market Size by Country
  6. 10.2.1 South America Antifibrotic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Antifibrotic Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Antifibrotic Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Antifibrotic Drug Sales by Country
  2. 11.1.1 Middle East and Africa Antifibrotic Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Antifibrotic Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Antifibrotic Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Antifibrotic Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Antifibrotic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Antifibrotic Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Antifibrotic Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Antifibrotic Drug Value Chain Analysis
  2. 12.1.1 Antifibrotic Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Antifibrotic Drug Production Mode & Process
  7. 12.2 Antifibrotic Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Antifibrotic Drug Distributors
  10. 12.2.3 Antifibrotic Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst